Physician profile
Robin E Smith
NPI 1518037647
$7,728.26
in general payments reported to CMS, 2019-2025
31 companies · $927 in 2025
The $927 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,200 · 2020: $925 · 2021: $1,345 · 2022: $1,319 · 2023: $849 · 2024: $1,163 · 2025: $927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,940.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,939.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,035.79 | 2019-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $913.78 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Corium, LLC | $879.85 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $811.85 | 2019-2024 | Jornay Pm |
| Ucb, INC. | $715.94 | 2021-2025 | Briviact, Fintepla, Nayzilam |
| Eisai INC. | $521.75 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $487.48 | 2019-2022 | |
| Neurelis, INC. | $465.29 | 2020-2025 | Valtoco |
| Greenwich Biosciences, INC. | $307.10 | 2019-2021 | |
| Adlon Therapeutics L.P. | $242.17 | 2019-2021 | |
| Aquestive Therapeutics, INC. | $184.66 | 2019-2024 | |
| Abbvie INC. | $182.14 | 2022-2025 | Botox |
| Vertical Pharmaceuticals, LLC | $135.39 | 2019-2025 | Relexxii |
| Neos Therapeutics, Lp | $121.44 | 2019-2024 | Adzenys Xr-Odt |
| Allergan, INC. | $112.35 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $108.01 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $66.15 | 2020 | |
| Azurity Pharmaceuticals, INC. | $61.18 | 2023-2025 | Zonisade, Eprontia |
| Zogenix INC. | $44.68 | 2021 | |
| Arbor Pharmaceuticals, INC. | $42.42 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $38.00 | 2020 | |
| Collegium Pharmaceutical, INC. | $34.76 | 2025 | Jornay Pm |
| Avion Pharmaceuticals | $34.27 | 2023-2024 | Methylphenidate Hydrochloride, Relexxii |
| Metacel Pharmaceuticals LLC | $34.02 | 2024-2025 | Ozobax, Ozobax |
| Sunovion Pharmaceuticals INC. | $30.08 | 2020-2022 | |
| Ptc Therapeutics, INC. | $25.24 | 2023 | Emflaza |
| Shire North American Group INC | $24.82 | 2019 | |
| Biocodex, INC. | $22.98 | 2025 | |
| Amneal Pharmaceuticals LLC | $17.45 | 2019 | |
| Ns Pharma, INC. | $14.37 | 2022 | |
| Cranial Technologies, INC | $12.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.